WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product … WebStock analysis for Cingulate Inc (CING:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... Cingulate Inc. …
Cingulate to Participate in Benzinga All Live Access Event
WebMar 10, 2024 · Cingulate® (CTx®) is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build … Web20 hours ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform... financial industry turnover rate 2022
Cingulate Inc. (CING) Stock Price, Quote & News - Stock Analysis
Web1 day ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. … Web20 hours ago · Cingulate is headquartered in Kansas City. For more information visit Cingulate.com Investor Relations Thomas Dalton Vice President, Investor & Public … WebApr 10, 2024 · Company profile for Cingulate Inc. (CING) with a description, list of executives, contact details and other key facts. financial inequality examples